ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 0.0 | 0.0 | 0.0 |
| Other income | 0.1 | 0.1 | 1.0 |
| Total income | 0.1 | 0.1 | 1.0 |
| Profit before exceptional items & tax | 0.1 | 0.0 | 0.9 |
| Profit before tax | 0.1 | 0.0 | 0.9 |
| Net profit | 0.3 | -1.6 | 0.7 |
| Operating margin | 100.0% | 0.0% | 90.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -57.10% |
|---|---|
| Operating profit, year on year | +100.00% |
| Operating profit, quarter on quarter | +100.00% |
BSE results filing, NSE: BACPHAR. Figures extracted from the filing.
Bacil Pharma Ltd: key numbers
- Share price
- ₹16.95
- Market cap
- ₹24.33 Cr
- Revenue (annual)
- ₹0.00 Cr
- Net profit (annual)
- ₹1.56 Cr
- P/E (TTM)
- 38.5×Sector 43.8×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bacil Pharma Ltd
All →Bacil Pharma Partnership
Bacil Pharma's wholly owned subsidiary signed an R&D agreement with Efdee Pharma for pharmaceutical products. The estimated project cost is Rs. 35 Crore.
- Value
- ₹35.00 Cr
Bacil Pharma Other Announcement
Bacil Pharma Ltd submitted its quarterly shareholding pattern for the period ending September 30, 2026, in compliance with SEBI Regulation 31.
Bacil Pharma Q2 FY27 Results: Net Loss of ₹0.1 Cr
Bacil Pharma Ltd reported a net loss of ₹0.1 Cr for Q2 FY27.
- Key figure
- Net loss ₹0.1 Cr
Bacil Pharma Management Change
Mr. Dikshant Singh Panwar has resigned as Whole-Time Company Secretary and Compliance Officer of Bacil Pharma Limited, effective October 8, 2026.
Bacil Pharma Board Meeting Date
Bacil Pharma will hold a board meeting on October 14, 2026, to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026.
Bacil Pharma Annual Report
Bacil Pharma Limited submitted its 39th Annual Report for FY 2025-26. The Annual General Meeting is scheduled for September 23, 2026, via video conferencing.